Abstract
It is estimated that about 5–10% of breast cancer cases may be due to inherited predisposition. Until now, two main susceptibility genes have been identified: BRCA1 and BRCA2. The first linkage and mutational studies suggested that mutations in these two genes would account for the majority of high-risk breast cancer families, but recent studies show how the proportion of families due to BRCA1 or BRCA2 mutations strongly depends on the population and the types of family analyzed. It is now clear that, in the context of families with a modest cancer profile, which are the most commonly found in the clinical practice, the percentage of mutations found is much lower than that suggested by the first studies. In the present study, we analyze a group of 32 Spanish families, which contatined at least three cases of female breast cancer (at least one of them diagnosed before the age of 50 years), for the presence of mutations in the BRCA genes. The total proportion of mutations was low (25%), although the percentage of mutations in the BRCA1 and BRCA2 genes was higher, considering the breast and ovarian cancer families and the male breast cancer families respectively. Our results are in agreement with the idea that a great proportion of moderate-risk cancer families could be due to low penetrance susceptibility genes distinct from BRCA1 or BRCA2. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abel KJ, Xu J, Yin GY, Lyons RH, Meisler MH and Weber BL (1995) Mouse BRCA1: localization sequence analysis and identification of evolutionarily conserved domains. Hum Mol Genet 4: 2265–2273
BIC: www.nchgr.nih.gov/Intramural_research/Lab_transfer/Bic/guidelines.html,
Blackwood MA and Weber BL (1998) BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol 16: 1969–1977
Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T and Weber B (1997) BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336: 1409–1415
Díez O, Domènech M, Alonso MC, Brunet J, Sanz J, Cortes J, del Rio E and Baiget M (1998) Identification of the 185delAG BRCA1 mutation in a Spanish Gypsy population. Hum Genet, (1998) 103: 707–708
Díez O, Osorio A, Robledo M, Barroso A, Domènech M, Cortés J, Albertos J, Sanz J, Brunet J, San Román JM, Alonso MC, Baiget M and Benítez J (1999) Prevalence of BRCA1 and BRCA2 Jewish mutations in Spanish breast cancer patients. Br J Cancer 79: 1302–1303
Easton DF, Bishop DT, Ford D and Crockford GP (1993) Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 52: 678–701
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA and Zelada-Hedman M and the Breast Cancer Linkage Consortium (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676–689
Garcia-Patino E, Gomendio B, Provencio M, Silva JM, Garcia JM, Espana P and Bonilla F (1998) Germ-line BRCA1 mutations in women with sporadic breast cancer: clinical correlations. J Clin Oncol 16: 115–120
Hogervost FBL, Cornelis RS, Bout M, van Vliet M, Oosterwijk JC, Olmer R, Bakker B, Klijn JGM, Vasen HFA, Meijers-Heijboer H, Menko FH, Cornelisse CJ, den Dunnen JT, Devilee P and van Ommen G-JB (1995) Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 10: 208–212
Lynch HT, Fain PR, Golgar D, Albano WA, Mailliard JA and McKenna P (1981) Familial breast cancer and its recognition in an oncology clinic. Cancer 47: 2730–2739
Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV and Ostrander EA (1998) BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 279: 922–929
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennet LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Brtistow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barret C, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A and Skolnik M (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66–71
Neuhausen SL, Godwin AK, Gershoni-Baruch R, Schubert E, Garber J, Stoppa-Lyonnet D, Olah E, Csokay B, Serova O, Lalloo F, Osorio A, Stratton M, Offit K, Boyd J, Caligo MA, Scott RJ, Schofield A, Teugels E, Schwab M, Cannon-Albright L, Bishop T, Easton D, Benitez J, King MC and Goldgar D (1998) Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet 62: 1381–1388
Osorio A, Robledo M, Albertos J, Diez O, Alonso C, Baiget M and Benitez J (1998) Molecular analysis of the six most recurrent mutations in the BRCA1 gene in 87 Spanish breast/ovarian cancer families. Cancer Lett 123: 153–158
Schubert EL, Lee MK, Mefford HC, Argonza RH, Morrow JE, Hull J, Dann JL and King MC (1997) BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 60: 1031–1040
Serova OM, Mazoyer S, Puget N, Dubois V, Tonin P, Shugart YY, Goldgar D, Narod SA, Lynch HT and Lenoir GM (1997) Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet 60: 486–495
Shattuck-Eidens D, Oliphant A, McClure M, Mc Bride C, Gupte J, Rubano T, Pruss D, Tavtigian SV, Teng DHF, Adey N, Staebell M, Gumpper K, Lundstrom R, Hulick M, Kelly M, Holmen J, Ligenfelter B, Manley S, Fujimura F, Luce M, Ward B, Cannon-Albright L, Steele L, Offit K, Giewski T, Norton L, Brown K, Schulz CH, Hampel H, Schluger A, Giulotto E, Zoli W, Ravaioli A, Nevanlinna H, Pyrhonen S, Rowley P, Loader S, Osborne MP, Daly M, Tepler I, Weinstein PL, Scalia JL, Michaelson R, Scott RJ, Radice P, Pierotti MA, Garber JE, Isaaes C, Peshkin B, Lippman ME, Dosik MH, Caligo MA, Greenstein RM, Pilarski R, Weber B, Burgemeister R, Frank TS, Skolnick M and Thomas A (1997)
Simard J, Tonin P, Durocher F, Morgan K, Rommens J, Gingras S, Samson C, Lebanc J-F, Bélager C, Dion F, Liu Q, Skolnick M, Goldgar D, Shattuck-Eidens D, Labrie F and Narod S (1994) Common origin of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 8: 392–398
Stratton MR, Ford D, Neuhasen S, Seal S, Wooster R, Friedman LS, King MC, Egilsson V, Devilee P and McManus R (1994) Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet 7: 103–107
Szabo CI and King MC (1997) Population genetics of BRCA1 and BRCA2. Am J Hum Genet 60: 1013–1020
The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91: 1310–1316
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rice C, Biggs P, Hashim Y, Smith A, Connor F, Arason A, Gudmundson J, Ficenec D, Kelsell D, Ford D, Tonin P, Bishop DT, Spurr NK, Ponder BAJ, Eeles R, Peto J, Devilee P, Cornelisee C, Lynch H, Narod S, Lenoir G, Egilsson V and Bjork MR (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789–792
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Osorio, A., Barroso, A., Martínez, B. et al. Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families. Br J Cancer 82, 1266–1270 (2000). https://doi.org/10.1054/bjoc.1999.1089
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.1089
Keywords
This article is cited by
-
Detection of inherited mutations for hereditary cancer using target enrichment and next generation sequencing
Familial Cancer (2015)
-
Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications
Cellular Oncology (2014)
-
Short telomeres are frequent in hereditary breast tumors and are associated with high tumor grade
Breast Cancer Research and Treatment (2013)
-
BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast–ovarian cancer families. Identification of novel mutations and unclassified variants
Breast Cancer Research and Treatment (2011)
-
Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility
Breast Cancer Research and Treatment (2009)